Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 10:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ABA Clear all
Completed Not applicable Interventional

Sensory Integration Therapy in Autism: Mechanisms and Effectiveness

NCT02536365
View directory record Official record
Conditions
Autism
Interventions
Sensory Integration Therapy, Applied Behavioral Analysis
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
6 Years to 114 Months
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 13, 2026, 10:40 PM EDT
Not listed Not applicable Interventional

Feasibility Testing and Pilot Study of V-MOTIVE Protocol Software Version 1

NCT02500771
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
ABA therapy enhanced with V-Motive software
Behavioral
Lead sponsor
Experiad LLC
Industry
Eligibility
4 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Jul 17, 2015 · Synced Oct 13, 2026, 10:40 PM EDT
Completed Not applicable Interventional

Improving Hospitalizations for Children With ASD

NCT02339935
View directory record Official record
Conditions
Autism Spectrum Disorder, Autistic Disorder
Interventions
Brief Analogue Functional Analysis, No Brief AFA
Behavioral · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
6 Years to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 13, 2026, 10:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Applied Behavioral Analysis (ABA) Versus ABA and Risperidone

NCT00374764
View directory record Official record
Conditions
Autistic Disorder
Interventions
Risperidone, ABA
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
30 Months to 5 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 16, 2007 · Synced Oct 13, 2026, 10:40 PM EDT
Recruiting Early Phase 1 Interventional

HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT

NCT06731504
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
Abatacept
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 13, 2026, 10:40 PM EDT
Completed Phase 3 Interventional Results available

Remission and Joint Damage Progression in Early Rheumatoid Arthritis

NCT00122382
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, placebo, methotrexate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
19
States / cities
Huntsville, Alabama • Huntington Beach, California • Colorado Springs, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2010 · Synced Oct 13, 2026, 10:40 PM EDT
Withdrawn Not applicable Interventional

Non-invasive Brain Stimulation in Children With Autism

NCT05105126
View directory record Official record
Conditions
Autism Spectrum Disorder, Executive Dysfunction, Child Autism
Interventions
Transcranial Direct Current Stimulation (tDCS), Sham tDCS
Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
5 Years to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 13, 2026, 10:40 PM EDT
Terminated Not applicable Interventional

T-ABA Group Based Early Intervention For Parents of Children With ASD

NCT02202421
View directory record Official record
Conditions
Autism
Interventions
Targeted Applied Behavior Analysis (T-ABA)
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
24 Months to 71 Months
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Oct 13, 2026, 10:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants

NCT04234672
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-831 Oral Tablet, [14C]TAK-831 IV Infusion, [14C]TAK-831 Oral Suspension
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 13, 2026, 10:40 PM EDT
Withdrawn Not applicable Interventional

Vagus Nerve Stimulator for Autism and Other Developmental Disorders

NCT06259201
View directory record Official record
Conditions
Autism Spectrum Disorder, Intellectual Disability, Autonomic Nervous System, Developmental Disability
Interventions
Vagus Nerve Stimulation
Device
Lead sponsor
New York State Institute for Basic Research
Government
Eligibility
12 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
New York, New York • Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 13, 2026, 10:40 PM EDT
Completed Not applicable Interventional

Aerofit Post Market Investigation

NCT05925712
View directory record Official record
Conditions
Transfemoral Amputation, Amputation, Skin Health
Interventions
AeroFit Seal-In Liner / Socket, Seal-In Silicone Liner
Device
Lead sponsor
Össur Iceland ehf
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Gainesville, Florida • Indianapolis, Indiana • Bay City, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 13, 2026, 10:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers

NCT05730842
View directory record Official record
Conditions
Healthy Volunteer, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, Inborn
Interventions
EDG-5506 Tablet, Radiolabeled EDG-5506 Suspension, Radiolabeled EDG-5506 Intravenous
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 13, 2026, 10:40 PM EDT
Completed Phase 3 Interventional Results available

Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

NCT00124982
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Anti-Tumor Necrosing Factor (TNF) Therapy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
114
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Oct 13, 2026, 10:40 PM EDT
Completed Phase 4 Interventional

COVID-19 VaccinE Response in Rheumatology Patients

NCT05080218
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
Interventions
Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab
Drug
Lead sponsor
Jeffrey Curtis
Other
Eligibility
18 Years to 85 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 13, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris

NCT01999868
View directory record Official record
Conditions
Psoriasis
Interventions
Ustekinumab, Abatacept, UST Placebo, ABA Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 13, 2026, 10:40 PM EDT
Completed Phase 3 Interventional Results available

Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis

NCT00095147
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept (ABA) + Methotrexate (MTX), double-blind (DB), Infliximab (INF) + MTX, DB, Placebo (PLA) + MTX, DB, PLA + MTX switched to ABA+ MTX, DB, ABA, open-label (OL)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
19
States / cities
Huntsville, Alabama • Denver, Colorado • Boca Raton, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 13, 2026, 10:40 PM EDT
Recruiting Not applicable Interventional

Effectiveness- Implementation Trial of the Function-Based Elopement Treatment

NCT07194083
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Function-Based Elopement Treatment, Treatment as Usual
Behavioral
Lead sponsor
Emory University
Other
Eligibility
4 Years to 12 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 13, 2026, 10:40 PM EDT
Completed Not applicable Interventional

Evaluating the Efficacy of Pathways Parent-Mediated Early Autism Intervention on Social Attention and Language

NCT05604326
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Pathways Intervention, Parent Education Intervention (PEI)
Behavioral
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
12 Months to 42 Months
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 13, 2026, 10:40 PM EDT
Terminated Not applicable Interventional

A Prospective Study to Evaluate Use of the Tibion Bionic Leg in Sub-Acute Post-stroke Patients

NCT01558232
View directory record Official record
Conditions
Stroke
Interventions
Tibion Bionic Leg
Device
Lead sponsor
Tibion Bionics, Inc.
Industry
Eligibility
40 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Oct 13, 2026, 10:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Assess the Janssen Autism Knowledge Engine in Participants With Autism Spectrum Disorder and in a Normally Developing Cohort

NCT02668991
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
6 Years and older
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Oct 13, 2026, 10:40 PM EDT
Not yet recruiting Not applicable Interventional

TeleABA for Hospitalized Adolescents and Young Adults With Autism Spectrum Disorder

NCT07701915
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD)
Interventions
Standard Hospital Care, Telehealth Applied Behavior Analysis (TeleABA)
Behavioral
Lead sponsor
Caring Technologies, Inc.
Industry
Eligibility
12 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Neptune City, New Jersey • Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 13, 2026, 10:40 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Centering Autistic Perspectives in Behavioral Intervention Discussions

NCT07165522
View directory record Official record
Conditions
Autism
Interventions
Transformative and Restorative Engagement Circle (TREC), Stakeholder Engagement in quEstion Development and prioritization (SEED)
Behavioral
Lead sponsor
Drexel University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 13, 2026, 10:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Abscisic Acid Effects on Glucose Homeostasis and Insulin Sensitivity

NCT04722354
View directory record Official record
Conditions
Pre Diabetes
Interventions
Hyperinsulemic euglycemic clamp, Muscle Biopsy, Oral abscisic acid (ABA), Placebo
Other · Procedure · Dietary Supplement
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 13, 2026, 10:40 PM EDT
Completed Not applicable Interventional

Intervention Effects of Intensity and Delivery Style for Toddlers With Autism

NCT02272192
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Early Start Denver Model (ESDM), Early Intensive Behavioral Intervention (EIBI)
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
15 Months to 30 Months
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
3
States / cities
Sacramento, California • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 13, 2026, 10:40 PM EDT